Exploring therapeutic uses.
The Staccato® system is breath actuated, and a patient simply inhales to administer the drug dose.
Unlike injections, the Staccato® system is non-invasive.
Products for the treatment of acute and intermittent conditions.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.
Read more about our company
We have already demonstrated that more than 200 FDA-approved compounds are feasible for delivery by the Staccato® system.
MOUNTAIN VIEW, Calif., Nov. 6, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today...
Management to Review Results and Provide Business Update in Conference Call Scheduled Today at 5:00...
Ferrer Purchases $8 Million of Alexza Common Stock through New Investment and Elimination of Potential...
"The past 18 months have been among the most successful and productive periods in our history."
Thomas B. King – Alexza President and CEO